New Job Opportunity

OrganOx Opens State-of-the-Art Research, Development, and Production Headquarters in Oxford, UK

OrganOx Ltd, a world-leading medical technology company developing innovative solutions for organ preservation prior to transplantation, and for the treatment of acute organ failure, is proud to announce the official opening of a new 18,000 square-foot global research, development, and production headquarters in Oxford, UK. Originally spun out from the University of Oxford in 2008, OrganOx developed the world’s first normothermic liver perfusion device, the metra®. The metra® launched across Europe in 2018 and in the U.S. in 2022 and has gained rapid market adoption since, enabling more organ transplants, eradicating night-time operating, and improving patient outcomes. “Our new facility opening is a major milestone, providing OrganOx stakeholders access to world-class facilities and technologies as we work together in ways that were simply not possible previously,” said Craig Marshall, CEO. “We are proud to be a growing member of the Oxford business and scientific community, and I am greatly looking forward to broader collaborations with commercial and clinical partners.” Prof. Peter Friend, FMedSci, Chief Medical Officer, and Co-Founder of OrganOx, commented, “We are all excited about what the future holds for OrganOx as we continue to push the scientific and clinical boundaries with technology-based solutions designed to improve the lives of patients experiencing acute or chronic organ failure. This remarkable new facility will support us in that mission for many years to come.” “Peter and I, surgeon and engineer, could scarcely imagine a day like this when we first began collaborating in an Oxford University laboratory more than 20 years ago,” said Prof. Constantin Coussios, OBE FREng FMedSci, Chief Technology Officer, and Co-Founder of OrganOx. “It is truly remarkable and a testament to the dedication and efforts of a great many researchers, engineers, transplant surgeons, staff, customers, patients, and business partners, whom we celebrate on this occasion.”

Novo Nordisk Announces $4.1 Billion Investment to Expand US Manufacturing, Adding 1,000 New Jobs

Novo Nordisk announced plans to invest 4.1 billion US dollars to build a second fill and finishing manufacturing facility in Clayton, North Carolina, and grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Marking one of the largest manufacturing investments in Novo Nordisk’s history, the expansion will add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, doubling the combined square footage of all three of the company’s existing facilities in North Carolina. It will also add 1,000 new jobs, besides the nearly 2,500 Novo Nordisk employees already working in the region, a central hub for innovation and biotechnology in the United States.“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building Novo Nordisk’s ability to serve millions more people living with serious chronic diseases in the future,” said Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk. “This is yet another real signal of our efforts to scale up our production to meet the growing global need for our life-changing medicines and the patients of tomorrow.” Utilising state-of-the-art technology, roof-top solar panels and innovative water strategies, the facility is designed in an efficient and environmentally sustainable way to deliver the highest-quality products to patients around the world. The goal is to obtain LEED Gold certification, recognised as a standard of excellence in constructing healthy, efficient, carbon and cost-saving green buildings.“Clayton was the first manufacturing site for Novo Nordisk in the US, and this new, large-scale investment confirms the continued importance of our production facilities there as cornerstones of our company’s growth,” said Henrik Wulff, executive vice president, Product Supply, Quality & IT, Novo Nordisk. “For decades, we have partnered to foster a well-trained, dedicated and diverse local workforce in North Carolina. In Clayton and across our global manufacturing sites, we are driven by one purpose: to deliver more for the millions of people living with chronic diseases – and this facility will help us achieve just that.” Early clearing and foundational work are already underway to prepare the 56-acre facility footprint. Construction will gradually be finalized between 2027 and 2029. Around 2,000 external contractors will be engaged at the height of the project. “It’s a historic day for Johnston County,” said Butch Lawter, Chair of the Johnston County Board of Commissioners, who, during today’s press conference, announced county grants to further support the expansion project. “Thirty-one years ago, Novo Nordisk decided to make a new home here in Clayton. Then, in 2016, they announced a new facility right across the street - the single largest life sciences investment on state record at the time. Today, they’re breaking that record again… with a third facility, 1,000 new jobs and a vote of confidence in the partnerships we have forged in the community over the decades.”In 2024, Novo Nordisk will increase actual investments in production and plans to invest approx USD 6.8 billion (DKK 45 billion) in production compared to actual investments of USD 3.9 (DKK 26 billion) last year* to increase supply.

Pall Corporation Opens New State-of-the-Art Facility in Singapore, Creating Up to 300 Jobs

Pall Corporation, a leader in filtration, separation and purification technologies, held its opening ceremony for a new state-of-the-art manufacturing facility in Singapore that will serve regional and global customers within the growing semiconductor industry. Pall has invested approximately US$150 million on the facility which will primarily produce lithography and wet-etch filtration, purification and separation solutions that will help meet the high demand for advanced node semiconductor chips. “Throughout an almost 80-year history, Pall has been on the forefront of solving some of the world’s most complex challenges using advanced filtration. This new facility is not only an important development for advancing semiconductor manufacturing technology, but also an important next step for Pall. We will continue to leverage our experience and expertise to help solve global challenges, from the increased demand for advanced chips to aiding in the transition to greener manufacturing,” said Mr. Naresh Narasimhan, Danaher Group Executive, High Growth Markets & Pall Corporation. The now-completed seven-acre facility will include more than 18,000 square meters of high-volume manufacturing (HVM) and office space and will integrate core research and development capabilities in the future. The new facility will allow customers in highly demanding industries to meet growing end market demand for data processing and storage. “Newer applications like generative artificial intelligence (AI), high-performance computing (HPC), next generation communications and autonomous vehicles require cutting-edge semiconductor chips that are made in advanced node fabs. The high technology filtration solutions manufactured by this new facility are specifically designed to support the production of these advanced node logic and memory chips,” said Mr. Shangaza Dasent, Vice President and General Manager Microelectronics, Pall Corporation. It is expected that the new site will create up to 300 jobs over the next few years across science, engineering and advanced manufacturing, with an emphasis on training and developing new talent as well as enabling transfer of knowledge to contribute to the growth of the sector as part of Singapore’s long-term strategy. There will be a consistent focus on talent development aligned to broader strategic national priorities to ensure that the advanced manufacturing industry can thrive in Singapore. With the addition of Pall’s new facility, Pall is building more capacity to support cutting-edge technologies and help scale new applications like generative AI. “We warmly welcome Pall’s new manufacturing facility to Singapore’s vibrant semiconductor ecosystem. This addition not only strengthens Singapore’s position as a critical node within the global semiconductor industry, but also improves the resiliency of the supply chain for the region. Singapore is committed to nurturing talent, building our R&D capabilities and ecosystem, and working with the industry to build a robust and diverse advanced manufacturing cluster,” said Mr. Tan Kong Hwee, Executive Vice President, Singapore Economic Development Board. Mr. Alvin Tan, Minister of State for Trade and Industry and Culture, Community and Youth, graced the opening ceremony as Guest of Honor and was joined by Casey Mace, Deputy Chief of Mission, U.S. Embassy in Singapore and Tan Kong Wee, Executive Vice President, Economic Development Board.

Thermo Fisher Scientific Announces New Clinical Research Laboratory, Creating 350 Scientist Jobs

The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, unveiled a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. The new 72,500-square-foot building increases the site’s chemistry, manufacturing and control (CMC) analytical capabilities as part of its clinical development and laboratory services focused on improving health by helping customers deliver life-changing medicines. “As research in biopharmaceutical therapies continues to rapidly expand, we are excited to expand our overall capacity and capabilities in laboratory services to help our customers deliver therapies that meet the highest quality and safety standards for patients,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “We will continue to support and empower our customers as they continue to discover, develop and deliver new groundbreaking therapies. This $58 million investment to expand the site is a testament to our dedication in supporting Thermo Fisher’s Mission of making the world healthier, cleaner and safer.” The GMP site offers high-quality analytical services for small molecules and biologics, including biopharmaceuticals, inhaled pharmaceuticals and device testing, cell and gene therapy, protein characterization and mass spectrometry analysis for all phases of drug development. The latest addition to the GMP campus provides a multi-use and flexible biosafety level 2 laboratory that includes a purpose-built liquid chromatography-mass spectrometry and protein characterization space, two large molecular suites with access controlled pre- and post-amplification labs, and two large general-use labs. The expansion will add up to 350 scientists and laboratory support professionals to the almost 2,300 employees working across the research campus. Earlier this year, Thermo Fisher announced the addition of biosafety testing to its GMP portfolio of services at the Middleton facility. With the addition of this capability, as well as the addition of the new building, the site offers a full complement of end-to-end laboratory services. “As Wisconsin’s biohealth sector continues to grow, so will our workforce, our economic momentum, and our opportunities to build a healthier, stronger state for all,” said Gov. Tony Evers. “This new state-of-the-art facility will not only further advance our state’s biosafety testing capabilities and create hundreds of jobs, but it will also help protect consumers and improve patient health outcomes across the state.” In addition to GMP and bioanalytical labs in Middleton, Thermo Fisher’s clinical research laboratory business includes bioanalytical, biomarker and vaccine sciences labs in Richmond, Virginia; a GMP lab in Athlone, Ireland; central labs and biomarker operations in Brussels, Belgium, Highland Heights, Kentucky, and Singapore; and bioanalytical, biomarker, vaccine sciences and central labs in Suzhou, China.

INOVAIT and Government of Canada Announce Investment in R&D Projects, Creating Jobs for Highly Skilled Professionals

INOVAIT and the Government of Canada announced a $10.7 million investment in contributions to seven commercialization-focused R&D projects under the second iteration of INOVAIT's Focus Fund program. Founded by the Sunnybrook Research Institute (SRI) and supported by the Government of Canada's Strategic Innovation Fund (SIF), INOVAIT is Canada's network focused on advancing image-guided therapy (IGT) through the integration of artificial intelligence (AI), big data, and machine learning. IGT is the practice of using medical imaging to plan, perform, and evaluate medical interventions. The INOVAIT network supports Canadian innovators who are unleashing the power of AI through IGT's precision therapy and treatment to streamline healthcare and improve healthcare outcomes. "Canada has tremendous strength in the research and development of medical imaging and AI technologies. We need to capitalize on this opportunity and leverage both these strengths to advance technologies that can improve clinical outcomes and healthcare efficiencies," says Kullervo Hynynen, Co-Executive Director of INOVAIT and Vice-President of Research and Innovation at SRI. Through this iteration of the Focus Fund program, the seven selected high potential projects will integrate machine learning capabilities into IGT technologies. Selected Focus Fund projects were evaluated based on their potential impact to innovation, healthcare, and economic development. Focus Fund project members will invest an additional $21.3 million into these projects for a total influx of $32 million into the Canadian IGT sector. The Focus Fund contributions will help attract investments into these Canadian technology companies, create jobs for highly skilled professionals, and cement Canada's status as a global leader in IGT and AI innovation. "INOVAIT's Focus Fund represents the natural evolution for promising pilot fund projects in the area of image guided therapy and helps attract key investments for these innovative Canadian technology companies. We applaud all recipients for the successful demonstration of their projects' technical and clinical merits, creating highly skilled jobs and we look forward to seeing all progress made in advancing the field through artificial intelligence and machine learning integration," said the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry. Selected Focus Fund projects include: MIMOSA Diagnostics: MIMOSA's Focus Fund project will deploy a handheld multispectral imaging tool for nurses in long-term care homes to assess and treat residents at-risk of developing or have active pressure injuries (PI). With the support of their project partners, they will train advanced machine learning models to prognosticate tissue at risk of PI to identify patients and prioritize intervention. Profound Medical: Profound Medical's Focus Fund project will improve outcomes for men undergoing MRI-guided transurethral ultrasound ablation (TULSA) by leveraging AI across the three stages of their prostate cancer journey. The INOVAIT 2024 Focus Fund announcement took place at Sunnybrook Health Sciences Centre. Pam Damoff, Parliamentary Secretary to the Minister of Foreign Affairs attended and spoke at the event. "Today, I was pleased to meet leaders in health care and to learn about new projects that will benefit Canadians," said Pam Damoff. "By providing a platform to connect, educate and invest in the most promising ventures, INOVAIT is pushing boundaries and working to improve health outcomes." As of December 2023, INOVAIT has launched 75 IGT-AI projects, committed over $29 million to projects and continues to support its 97 project members across Canada in advancing IGT innovation, economic development, and job creation in Canada.

Exyte to create up to 1,000 jobs across the USA to facilitate growth

Exyte GmbH (Exyte), a global leader in the design, engineering, and delivery of high-tech facilities, is poised for a robust expansion trajectory in the USA. In line with its "follow-the-client" strategy, Exyte is ramping up its service and production network as well as its workforce in key strategic locations across the country. In the medium run, the company plans to create approximately 1,000 additional positions in the USA. With the official opening of its new regional office in Boise, Idaho, Exyte expands its national footprint to the Northwest. In addition, new offices and production sites are being established in Nampa, Idaho, to support US-wide mega-projects in high-tech industries such as the semiconductor industry. With new offices in Durham, North Carolina, and Conshohocken, Pennsylvania, Exyte is addressing the needs of the US pharmaceutical and biotech industry. In Dallas, Texas, the company plans to relocate to a new headquarter. "Given its high market potential, the USA is an integral part of Exyte's growth strategy. In line with our future agenda 'Next Level', we are establishing a strategic network of production and offsite manufacturing sites as well as offices across the USA to be prepared for future projects and to increase the speed of project implementation for our clients," outlines Exyte CEO Dr. Wolfgang Büchele. "To facilitate our projected growth, we are offering hundreds of highly qualified jobs across several regions in the country," Büchele continues. "Our employees are the heartbeat of Exyte, and we look forward to onboard exceptional talents from all fields and backgrounds who can support us in our vision to create a better future." Ongoing investments in all target industries The USA is currently experiencing a significant increase in investments in high-tech facilities such as semiconductor and battery cell factories, driven in part by the U.S. CHIPS and Science Act and the Inflation Reduction Act. The CHIPS Act alone will provide federal subsidies of around $53 billion for semiconductor manufacturing, research, and development as well as workforce. "The high incentives underscore the USA's commitment to maintaining leadership in this key global technology," comments Mark Garvey, member of Exyte's executive board and CEO Advanced Technology Facilities, on the occasion of the office opening in Boise. According to prognosis by research company Aritzon, the U.S. data center market will witness investments of $110 billion by 2028, growing at a CAGR of 3.57 percent per annum. In addition to investments in data centers to expand digital infrastructure, there is also an increase of production capacities in the pharmaceutical sector. "The USA is definitely an important and exciting growth region today and into the future for Exyte. Our company's skills and our professional staff are perfectly aligned with the national high-tech agenda here in the US," Garvey continues. 1,000 additional jobs for the USA Exyte's projects often involve multi-billion-dollar investments and require a vast support network. When staffing project teams, Exyte prioritizes regional recruitment. Overall, Exyte plans to create around 1,000 jobs to add to its current headcount of more than 2,300 for its upcoming US-projects over the coming months. Offered positions are ranging from project engineers to project managers, designers, and technicians. In some regions where Exyte has its own offices or implements projects, the company also collaborates with local universities. The focus is primarily on STEM subjects. Starting from 1989, Exyte has been operating in the USA as a trusted leader in turnkey solutions, serving the most technically demanding clients. With locations in about 20 cities, covering office, production and service facilities, Exyte has a strong foothold in the USA and has earned the trust of leading US and internationally based companies operating in markets such as semiconductors, batteries, biopharma and life sciences, as well as data centers. "Our clients value predictability, efficiency, and world class performance in Environmental, Health and Safety (EHS) in project execution. Through our full-service offering and Exyte's network of specialized subsidiaries, we are able to provide tailormade turnkey solutions for the most complex high-tech projects anywhere in the world," outlines Garvey.

Corealis Pharma Inaugurates New Facilities and Expands Workforce Initiatives

In the presence of the esteemed Christopher Skeete, Minister for the Economy, and Christine Poirier, Laval City Councillor, Corealis Pharma Inc. proudly inaugurates the expansion of its facilities nestled in the heart of Laval's Biotech City. This significant expansion, the result of an investment exceeding $10 million, extends the premises of the Quebec-based company from 33,000 to 63,000 square feet, facilitating the installation of new state-of-the-art laboratories, and heralding a new era for Corealis, both within Quebec and on a global stage. "My co-founders and I are immensely proud to inaugurate these state-of-the-art laboratories. These facilities will bolster our research and development capabilities for new drugs, catering to global growth and enhancing our market presence," stated Corealis President Yves Roy. Established in 2005 by three pioneering scientists - Yves Roy, Patrick Gosselin, and Yves Mouget - the Laval-based company swiftly garnered the trust of small and medium-sized biotechs globally, as well as major pharmaceutical entities, to emerge as one of the world's foremost Contract Research and Development Organizations (CRO/CDMOs). In 2022, to expedite its expansion, Corealis forged a partnership agreement with the CDPQ and Archimed a global investment firm focused on healthcare industries. With a clientele predominantly located in New England and California, alongside various other regions worldwide, the company recorded a notable 20% increase in sales for 2023. This expansion underscores the company's excellence, dedication, and contribution to the burgeoning life sciences industry in Quebec. "I am proud to celebrate Corealis' success today! By supporting companies in the life sciences, a key sector of our economy, we are strengthening the international influence of Quebec's expertise. Corealis perfectly embodies this dynamic," declared Mr. Christopher Skeete, Minister for the Economy. In addition to fostering its workforce expansion, the new space will enable Corealis Pharma to expedite: Advancements in formulation development and manufacturing of oral solid dosage forms Early-stage projects Analytical method development Integration of state-of-the-art analytical and formulation equipment The pace and scale of drug research and development Expanded clinical trial material manufacturing and packaging The inauguration of Corealis' new facilities today marks the realization of a three-stage strategic plan aimed at attaining the company's primary objective: to emerge as the global benchmark in the development of oral solid dosage form formulations, thereby reinforcing Quebec's status as a center of excellence in biotechnology. This event serves as an occasion to celebrate not only the company's success but also its unwavering commitment to innovation and excellence in the life sciences arena. "Corealis elevates the profile of Quebec and the city of Laval, in particular. We take immense pride in supporting the directors and employees of this esteemed company, facilitating its continued growth on our soil, thus reaffirming Biotech City as a premier destination for investment and advancement in Quebec's life sciences landscape," concluded Laval City Councillor Christine Poirier.

Sartorius Opens New Center of Excellence for Bioanalytic, Plans to Double Workforce

The life science group Sartorius opened its new Center of Excellence for bioanalytics in Ann Arbor, Michigan, two years after breaking ground in the Tech Loop at Research Park. Sartorius has invested around 100 million US dollars in the state-of-the-art facility, consolidating existing sites and functions in Ann Arbor. The number of employees at the site is expected to double over time. "Sartorius is a leading provider of highly automated bioanalytical solutions that are used in the discovery and development of innovative biopharmaceutical drugs. We are helping scientists to gain better, data-driven insights and streamline their workflows, ultimately accelerating the development of new, life-saving therapies. With our new flagship site in Ann Arbor, we are bringing together our core competencies and dedicated experts under one roof, further strengthening our ability to address key customer needs in this highly innovative and relevant field," said Dr. Alexandra Gatzemeyer, Head of the Lab Products & Services division and member of the Executive Board of Sartorius. The 130,000-square-foot facility houses a modern manufacturing and services area, biology labs, a warehouse, office and training spaces, as well as a Customer Interaction Center (CIC). Sartorius will develop and manufacture a range of bioanalytical instruments at this site, including the associated reagents, consumables and software solutions. In addition, the company will provide particle validation services and produce microcarriers used in cell culture processes. The Center of Excellence was built with a focus on sustainability and is seeking a Leadership in Energy and Environmental Design (LEED) gold certification, to be administered by the U.S. Green Building Council. Sustainable features include green electric energy supply from 200 kilowatt solar panels, 30 electric vehicle charging stations, and Research Park's first storm runoff pond. "Ann Arbor is strategically located at the crossroads of talent, technology and logistics, in close proximity to customers and renowned universities. The opening of our new building in the Tech Loop marks an important milestone for Sartorius in the Americas region, offering space for further expansion in the future," said Maurice Phelan, President of Sartorius North America.

Bionova Scientific announces plans for new Plasmid DNA GMP facility

Bionova Scientific, an Asahi Kasei Group company and full-service biologics CDMO, announced plans to expand into plasmid DNA (pDNA) production. The centerpiece of the project is a new development and manufacturing facility in The Woodlands, Texas (near Houston). When the new facility begins operation (planned for Q1/2025), Bionova Scientific will offer pDNA development services and production of research grade and high quality pDNA. GMP manufacturing is planned for later in 2025. The expansion is part of a previously announced long-term strategic initiative by the company – supported by the Asahi Kasei Group – to broaden its services portfolio to cover an even wider range of technical capabilities and therapeutic modalities, in response to diversifying customer requests. Specifically, the pDNA initiative is in response to the persistent unmet need for high quality, timely, and reliable pDNA supply among developers of novel cell and gene therapies (CGT). After evaluating multiple locations, Bionova selected The Woodlands due to its geographical proximity to CGT companies across the United States, as well as local access to the rapidly expanding CGT ecosystem in Texas. “For the past few years, we’ve seen the cell and gene therapy marketplace struggle with constrained availability of high quality pDNA. In response, we have been building internal expertise and creating a thoughtful market entry plan, culminating with today’s announcement of our new Houston facility,” said James Glover, Bionova’s Chief Operating Officer. “We are confident that by this time next year, we will be well into the delivery of expert development services and production of high quality pDNA.” Bionova Scientific is also currently expanding biologics production capacity at its Fremont, California headquarters, as announced in early 2023. That expansion will quadruple GMP manufacturing capacity and position the company for manufacture of commercial biotherapeutics. Darren Head, CEO of Bionova Scientific commented, “Bionova’s mission has always been to help our partners get their therapeutics to patients faster. In our traditional biologics operation, we’ve had great success helping partners overcome technical hurdles and streamlining timelines to get them into the clinic rapidly. That requires that we not only work smarter, but that we have the physical assets needed to avoid delays. We are taking the same approach with plasmid DNA, starting with building a committed, expert team and then designing and establishing a facility that will translate to the same kinds of successes.” Head also acknowledged the support of several local organizations in the lead-up to Bionova’s decision: “As we evaluated The Woodlands as a potential home for Bionova’s new pDNA operation, the enthusiastic support of The Montgomery County Commissioners, The Woodlands Township and The Woodlands Area Economic Development Partnership was instrumental. We appreciate their welcoming help and look forward to a continued collaboration as we proceed forward.” “Bionova is driven to support our partners to bring life-saving treatments to patients. By adding pDNA to our strategic offering, we are enhancing marketplace access to critical starting material across the landscape of clinical and commercial therapeutics,” added Michelle Chen, Bionova’s Senior Vice President of Process Development and Manufacturing for Plasmid DNA.

Thermo Fisher expanding its clinical trial network in Europe

Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies. The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies and vaccines. To meet increasing demand from cell and gene therapy clinical trials in Europe, this state-of-the-art facility builds on the company’s market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage. The facility enables customers to meet clinical trial requirements regardless of scale or phase by leveraging its highly skilled and talented local workforce to partner with new and emerging biotech and established pharmaceutical companies. “The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics, coupled with our proven track record in managing valuable materials, places us in an unmatched position to help our global clients develop innovative therapies,” said Molly Flick, vice president and general manager, bioservices & specialty logistics. The site, 30 minutes outside of Amsterdam, offers clinical and commercial packaging services for cell and gene therapy products from development to commercialization, as well as end to end biorepository storage solutions and associated supply chain services. Capabilities include 5,000-square-meters (54,000 square feet) of ambient to cryogenic storage, ancillaries, and cold chain packaging, labeling, distribution as well as clinical QP release services. In support of Thermo Fisher’s commitment to sustainability and its global goal of achieving net-zero emissions by 2050, the Bleiswijk site uses 15% solar power and operates completely gas-free, provides sustainable heating and cooling with eco-friendly electric heat pumps, and uses ultramodern heat recovery technology.

Health & Biotech